Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
18 févr. 2014 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...
Elite Pharmaceuticals, Inc. Appoints Nasrat Hakim as President and Chief Executive Officer
05 août 2013 07h00 HE
|
Elite Pharmaceuticals, Inc.
Elite Adds Twelve Approved Products to Its Pipeline
Conference Call Scheduled for 1 PM Eastern Time
NORTHVALE, N.J., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP)...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corporate History
21 juin 2013 13h44 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 21, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on Monday, June 24, 2013
19 juin 2013 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 19, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Naltrexone
06 févr. 2013 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that on January 31, 2012, the U.S. Food and Drug Administration approved the...